Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 17 | ||||||||||
answering dept short name | Health and Social Care | ||||||||||
answering dept sort name | Health and Social Care | ||||||||||
ddp modified |
|
||||||||||
hansard heading | Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction | ||||||||||
house id | 1 | ||||||||||
identifier | 291225 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask the Secretary of State for Health and Social Care, what steps his Department has taken, in light of the European Medicines Agency formally declaring that it recognises Post SSRI Sexual Dysfunction (PSSD) as a medical condition that can outlast discontinuation of SSRI and SNRI antidepressants, to provide symptomatic relief to those suffering from that condition on a long-term basis. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member constituency | Birmingham, Selly Oak | ||||||||||
tabling member printed |
|
||||||||||
title | House of Commons Tabled Parliamentary Question 2017/19 291225 | ||||||||||
type |
|
||||||||||
uin | 291225 | ||||||||||
version | 2 | ||||||||||
written parliamentary question type | NamedDay | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher | 25259 | ||||||||||
tabling member |
|